Manojkumar Bupathi

1.3k citations
46 papers · 850 · 2 hit papers · h-index 13

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • CAR-T cell therapy research
    • Peptidase Inhibition and Analysis
  • Surgery top 10%
    • Bladder and Urothelial Cancer Treatments
    • Urinary and Genital Oncology Studies

Papers in

    • Cancer Immunotherapy and Biomarkers 19
    • Colorectal Cancer Treatments and Studies 5
    • Bladder and Urothelial Cancer Treatments 21
    • Urinary and Genital Oncology Studies 5
    • Cholangiocarcinoma and Gallbladder Cancer Studies 4

Manojkumar Bupathi

42 papers receiving 837 citations

Manojkumar Bupathi's Hit Papers

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes 2024 · 45 citations
450+1+3Years since publication100200300

Peers

Manojkumar Bupathi
Comparison fields: 5 of 59
  • Oncology 389
  • Surgery 403
  • Cancer Research 66
  • Hepatology 34
  • Pulmonary and Respiratory Medicine 126
Replace Takahiro Einama with:
Takahiro Einama Japan
Anna Zamboli Italy
Anthony A. Meluch United States
Hong Xie United States
Takashi Ichimura Japan
Emmanuelle Samalin France
Capucine Baldini France
Chen-Yuan Lin Taiwan
Lara Alessandrini Italy
Maria D. Begnami Brazil
Manojkumar Bupathi relative to Takahiro Einama Japan Takahiro Einama's profile →
Citations per field
00.5×2.6×
Takahiro Einama · 1×
Citations per year

Countries citing papers authored by Manojkumar Bupathi

Since Specialization
Citations

This map shows the geographic impact of Manojkumar Bupathi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manojkumar Bupathi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manojkumar Bupathi more than expected).

Fields of papers citing papers by Manojkumar Bupathi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manojkumar Bupathi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manojkumar Bupathi. The network helps show where Manojkumar Bupathi may publish in the future.

Co-authors

The 25 scholars most cited alongside Manojkumar Bupathi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Manojkumar Bupathi Line = papers co-authored together Manojkumar Bupathi links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.

#Work
1
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Hit paper breakdown →
2021367
2 201561
3 201647
4
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Hit paper breakdown →
202445
5 202437
6 201931
7 202230
8 201428
9 202019
10 202315
11 202015
12 201714
13 202313
14 202312
15 202411
16 202310
17 202410
18 20179
19 20169
20 20178

About Manojkumar Bupathi

Manojkumar Bupathi is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Epidemiology and Pathology and Forensic Medicine, having authored 46 papers that have together received 850 indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (21 papers), Cancer Immunotherapy and Biomarkers (19 papers), Multiple and Secondary Primary Cancers (6 papers), Renal cell carcinoma treatment (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Prostate Cancer Treatment and Research (5 papers), Urinary and Genital Oncology Studies (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). The work is most often cited by research in Oncology (389 citations), Surgery (403 citations), Cancer Research (66 citations), Hepatology (34 citations) and Pulmonary and Respiratory Medicine (126 citations). Manojkumar Bupathi has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Daniel P. Petrylak, Scott T. Tagawa, Petros Grivas, Yohann Loriot, Cora N. Sternberg, Philippe Barthélémy, Damien Pouessel, Aude Fléchon, Neeraj Agarwal and Arjun Vasant Balar. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Oncologist, Medical Oncology and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact